Rifampin
ANDA 219918, held by Novitium Pharma. Rifampin.
- First approved: Jun 29, 2026
- Review: Standard
- Supplements approved: 0
- Complete response letters: 0
Approvals and New Uses
The original application and every efficacy supplement, newest first| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2026 | Original application | Approved | None posted |
Products
2 strengths and formsIdentifiers
- Application
- ANDA 219918
- Drugs@FDA
- Overview at FDA
- Company
- Novitium Pharma
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters